Villain, Nicolas http://orcid.org/0000-0002-7429-4289
Béra, G.
Habert, M.-O.
Kas, A.
Aubert, J.
Jaubert, O.
Valabregue, R.
Fernandez-Vidal, S.
Corvol, J.-C.
Mangone, G.
Lehéricy, S.
Vidailhet, M.
Grabli, D.
Vidailhet, Marie
Corvol, Jean-Christophe
Arnulf, Isabelle
Lehéricy, Stéphane
Mangone, Graziella
Ihle, Jonas
Weill, Caroline
Grabli, David
Cormier-Dequaire, Florence
Mariani, Louise Laure
Degos, Bertrand
Levy, Richard
Pineau, Fanny
Socha, Julie
Benchetrit, Eve
Czernecki, Virginie
Rivaud-Pechoux, Sophie
Hainque, Elodie
Semenescu, Smaranda Leu
Dodet, Pauline
Bekadar, Samir
Brice, Alexis
Lesage, Suzanne
Mochel, Fanny
Ichou, Farid
Perlbarg, Vincent
Colsch, Benoit
Tenenhaus, Arthur
Gaurav, Rahul
Pyatigorskaya, Nadya
Yahia-Cherif, Lydia
Valabregue, Romain
Galléa, Cécile
Habert, Marie-Odile
Petrovska, Dijana
Jeancolas, Laetitia
Brochard, Vanessa
Chalançon, Alizé
Dongmo-Kenfack, Carole
,
Article History
Received: 22 June 2021
Accepted: 21 October 2021
First Online: 27 October 2021
Declarations
:
: Independent of this work, NV received research support from Fondation Bettencourt-Schueller, Fondation Servier and Fondation pour la Recherche sur l’Alzheimer; travel grant from the Movement Disorders Society, Merz-Pharma and GE Healthcare SAS; and is an unpaid sub-investigator in NCT04241068 (aducanumab, Biogen), NCT04437511 (donanemab, Eli-Lilly), NCT04592341 (gantenerumab, Roche), NCT03887455 (lecanemab, Eisai), NCT03352557 (gosuranemab, Biogen), NCT03828747 and NCT03289143 (semorinemab, Roche), NCT04619420 (JNJ-63733657, Janssen—Johnson & Johnson), NCT04374136 (AL001, Alector), NCT04592874 (AL002, Alector). M-OH receives Consultant Fees from the Blue Earth Company. JCC has served in advisory boards for Air Liquide, Biogen, Denali, Ever Pharma, Idorsia, Prevail Therapeutic, Theranexus, UCB; and received grants from Ipsen, the Michael J Fox Foundation, and Sanofi. SL received grants from ‘Investissements d’avenir’ [grant number ANR-10-IAIHU-06 and ANR-11-INBS-0006], Fondation Bettencourt Schuller (Ultrabrain project) and Biogen Inc. DG received grants “Contrat Interface” from INSERM, AP-HP (DRC-PHRC) and France Parkinson, served on scientific advisory boards for AbbVie and Zambon; received research funding from Air Liquide; received speech honorarium from UCB, Teva, Medtronic, Abbvie and Merz; received travel funding from Teva, Novartis, Abbvie and Merz. GB, AK, JA, OJ, RV, SFV, GM, and MV declare no conflict of interest related to this work.
: The study was approved by the local ethic committee Comité de Protection des Personnes (CPP) “Ile-de-France VI” (IRB: 2014-A00725-42/48-14). Informed consent was obtained from all individual participants included in the study.
: All the authors have read and agreed with current content of the submitted manuscript.